应用低分子肝素钠预防房颤患者住院期间心源性脑栓塞的临床研究  

Clinical research on the application of low -molecular -weight heparin sodium to prevent the incidence of CCE for patients with atrial fibrillation

作　　者：易晓淑[1] 章丽萍[1] 孙慧超[2] 

机构地区：[1]重庆医科大学教学医院重庆市丰都县人民医院内二科,重庆408200 [2]重庆医科大学附属儿童医院心血管内科,重庆400014

出　　处：《中国医药导报》2013年第20期149-150,153,共3页China Medical Herald

基　　金：国家重点基础研究发展计划(973计划)(编号2010CB529505)

摘　　要：目的探讨低分子肝素钠预防房颤患者住院期间心源性脑栓塞(CCE)的临床效果。方法选取重庆市丰都县人民医院心内科2001～2011年有华法林抗凝指征但不愿接受华法林抗凝治疗的房颤患者共658例为研究对象,将其分为A组(n=352)和B组(n=306),A组给予低分子肝素钠联合阿司匹林肠溶片,B组单纯服用阿司匹林肠溶片。比较两组患者CCE的发生率。结果 A组CCE发生率为5.1%(18/352),B组CCE发生率为9.8%(30/306),两组CCE发生率比较差异有统计学意义(χ2=5.32,P<0.05)。结论对不愿接受华法林抗凝治疗患者在住院期间使用低分子肝素钠可减少住院期间脑栓塞的发生。Objective To investigate die application of low-molecular-weight heparin sodium to prevent the incidence of CCE for patients with atrial fibrillation. Methods 658 patients with atrial fibrillation who had anticoagulant indications and unwilling to accept Warfarin therapy during hospitalization from 2001 to 2011 in the Department of Cardiology in People＇s Hospital of Fengdu County in Chongqing City. These patients were divided into group A （n = 352） and group B （n = 306）. Patients in group A were treated with low-molecular-weight heparin sodium combined with aspirin, patients in group B were treated only with aspirin. The occurrence rate of CCE in the two groups were analyzed. Re- suits The occurrence rate of CCE in group A was 5.1% （18/352）, the occurrence rate of CCE in group B was 9.8% （30/306）, the difference was statistically significant （χ^2= 5.32, P 〈 0.05）. Conclusion Low-molecular-weight heparin sodium can reduce the incidence of CCE for patients who are unwilling to accept Warfarin anticoagulant therapy during hospitalization.

关 键 词：心源性脑栓塞 房颤 低分子肝素钠 

分 类 号：R541.75[医药卫生—心血管疾病]